These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37604171)

  • 1. 25-hydroxyvitamin D sufficiency is associated with lower de novo anti-HLA donor specific antibody and better kidney transplant outcomes.
    Bakis H; Bouthemy C; Corcuff JB; Lauro C; Guidicelli G; Cargou M; Guibet C; Taton B; Merville P; Couzi L; Moreau K; Visentin J
    HLA; 2024 Jan; 103(1):e15187. PubMed ID: 37604171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
    Kang ZY; Ma S; Liu W; Liu C
    Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the immunotherapy induction on allograft outcome and survival in kidney transplant patients with donor-specific antibodies to HLA-DQB1.
    Dutra RS; Fabreti-Oliveira RA; Lasmar MF; Araujo SA; Nascimento E
    Transpl Immunol; 2021 Jun; 66():101390. PubMed ID: 33838296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation.
    Jung HY; Kim SH; Seo MY; Cho SY; Yang Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2018 Aug; 33(34):e217. PubMed ID: 30127706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes.
    Redondo-Pachón D; Pérez-Sáez MJ; Mir M; Gimeno J; Llinás L; García C; Hernández JJ; Yélamos J; Pascual J; Crespo M
    Hum Immunol; 2018 Jun; 79(6):424-431. PubMed ID: 29524568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo donor-specific HLA antibodies reduce graft survival rates and increase the risk of kidney transplant rejection: A single-center retrospective study.
    Liu W; Zhao J; Kang ZY; Xiao YL; Yang L; Liu C; Li DH
    Transpl Immunol; 2021 Oct; 68():101430. PubMed ID: 34147608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.
    Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY
    Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation.
    Cioni M; Comoli P; Tagliamacco A; Innocente A; Basso S; Fontana I; Magnasco A; Trivelli A; Nocco A; Macchiagodena M; Catenacci L; Klersy C; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Nocera A
    Transpl Immunol; 2021 Apr; 65():101375. PubMed ID: 33610675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pre-Transplant Non-HLA Antibody Burden Associates With the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation.
    Senev A; Ray B; Lerut E; Hariharan J; Heylen C; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Front Immunol; 2022; 13():809059. PubMed ID: 35250981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients.
    Lee H; Lee H; Eum SH; Ko EJ; Min JW; Oh EJ; Yang CW; Chung BH
    Ann Lab Med; 2023 Jul; 43(4):364-374. PubMed ID: 36843405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Antibodies against Angiotensin II Type-1 Receptor on the Outcome of Kidney Transplantation: A Single-Center Retrospective Study.
    Filiopoulos V; Vittoraki A; Vallianou K; Bellos I; Markaki P; Liapis G; Marinaki S; Iniotaki A; Boletis IN
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.
    Senev A; Van Loon E; Lerut E; Coemans M; Callemeyn J; Daniëls L; Kerkhofs J; Koshy P; Kuypers D; Lamarthée B; Sprangers B; Tinel C; Van Craenenbroeck AH; Van Sandt V; Emonds MP; Naesens M
    Am J Kidney Dis; 2022 Dec; 80(6):718-729.e1. PubMed ID: 35690154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGG3 anti-HLA donor-specific antibodies and graft function in pediatric kidney transplant recipients.
    Hamdani G; Goebel JW; Brailey P; Portwood EA; Hooper DK; Girnita AL
    Pediatr Transplant; 2018 Aug; 22(5):e13219. PubMed ID: 29855114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients.
    Wan SS; Chadban SJ; Watson N; Wyburn K
    Am J Transplant; 2020 May; 20(5):1351-1364. PubMed ID: 31867849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
    Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.